A CSF disease-associated macrophage signature defines progressive multiple sclerosis
Authors:
- Anna-Lena BörschABAnna-Lena Börsch
- Frederike RiethuesFRFrederike Riethues
- Andreas Schulte-MecklenbeckASAndreas Schulte-Mecklenbeck
- Xuesong WangXWXuesong Wang
- Michael HemingMHMichael Heming
- I-Na LuILI-Na Lu
- Louisa Müller-MinyLMLouisa Müller-Miny
- Heinz WiendlHWHeinz Wiendl
- Catharina C. GrossCGCatharina C. Gross
- Raphaël Bernard-ValnetRBRaphaël Bernard-Valnet
- Gerd Meyer zu HörsteGHGerd Meyer zu Hörste
Open Access
- 13 May 2026
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1)
Abstract
Objective: Progression in multiple sclerosis (MS) often corresponds to irreversible disability in MS patients. Cellular changes in the cerebrospinal fluid (CSF) have provided biomarkers and mechanisms in relapsing-remitting MS (RRMS) but remain understudied in primary and secondary progressive MS (summarized herein as PMS). Methods: We combined retrospective flow cytometry of CSF cells from RRMS ( n = 169), PMS ( n = 56), and non-inflammatory controls ( n = 74) with prospective CSF single-cell transcriptomics of 35 individuals (11 controls, 12 RRMS, and 12 PMS) and with confirmatory CSF ELISA. Available CSF single-cell data from age-matched and Alzheimer’s disease (AD) patients served as additional controls. Results: Proportions of CD14 + monocytes in CSF are increased in PMS and correlated with clinical surrogate markers of progression. Transcriptionally, these monocytes resembled border-associated macrophages (BAM)-like cells with a chronically activated antigen-presenting phenotype. Additionally, these monocytes shared some features with disease-associated microglia/macrophages (DAM), previously identified in neurodegeneration. Induction of DAM-associated molecules, including transcribed and soluble TREM2 (sTREM2), characterized secondary progressive MS (SPMS) and supported its differential diagnosis. Interpretation: We thus identified MS stage-specific CSF signatures and shared cellular features of degeneration detectable in CSF of PMS patients. GraphicalKeywords
Funding Information
- Universitätsklinikum Münster
This publication has 58 references indexed in Scilit:
- Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJAMA Neurology, 2025
- Atlas of Cerebrospinal Fluid Immune Cells Across Neurological DiseasesAnnals of Neurology, 2024
- BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repairActa Neuropathologica, 2024
- A structured evaluation of cryopreservation in generating single-cell transcriptomes from cerebrospinal fluidCell Reports Methods, 2023
- Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairmentCell, 2022
- “Ependymal‐in” Gradient of Thalamic Damage in Progressive Multiple SclerosisAnnals of Neurology, 2022
- Association of Chronic Active Multiple Sclerosis Lesions With Disability In VivoJAMA Neurology, 2019
- The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative DiseasesImmunity, 2017
- A Unique Microglia Type Associated with Restricting Development of Alzheimer’s DiseaseCell, 2017
- Microglia derived from aging mice exhibit an altered inflammatory profileGlia, 2007